What the Study Found (In Plain English)
Published in European review for medical and pharmacological sciences (2021), this meta-analysis evaluating 762 human participants investigated: We aimed to assess the efficacy and safety of oral glucokinase activator (GKA) in the treatment of type 2 diabetes mellitus (T2DM). Key clinical takeaway: Oral GKAs combined with metformin has an evident hypoglycemic effect on T2DM, and they seem to be relatively good tolerant. Further clinical studies are still necessary to explore its long-term efficacy and safety.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (European review for medical and pharmacological sciences, 2021-01-15; N = 762; Rigor 97/100): Oral GKAs combined with metformin has an evident hypoglycemic effect on T2DM, and they seem to be relatively good tolerant. Further clinical studies are still necessary to explore its long-term efficacy and safety.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Meta-Analysis). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.